Underwriters have 30-day greenshoe for up to 967,741 more shares
By Susanna Moon
Chicago, April 15 – Foamix Pharmaceuticals Ltd. said it priced a $60 million public offering of common stock with a 30-day over-allotment option. The deal was announced in an F-1 filing with the Securities and Exchange Commission on April 1.
The company sold 6,451,612 shares at a price to the public of $9.30 per share, which is a 1.06% discount to the company’s $9.40 closing stock price on Tuesday.
Underwriters have a 30-day greenshoe for up to 967,741 more shares.
Barclays, Cowen and Co. and Guggenheim Securities are the bookrunning managers.
Proceeds will be used for clinical trials, studies and general corporate proceeds, including product development and promotion.
The clinical-stage specialty pharmaceutical company is based in Rehovot, Israel.
| Issuer: | Foamix Pharmaceuticals Ltd.
|
| Issue: | Common stock
|
| Amount: | $60 million
|
| Greenshoe: | 967,741 shares
|
| Shares: | 6,451,612
|
| Price: | $9.30
|
| Warrants: | No
|
| Bookrunners: | Barclays, Cowen and Co. and Guggenheim Securities
|
| Co-manager: | Oppenheimer & Co. Inc.
|
| Pricing date: | April 15
|
| Settlement date: | April 20
|
| Stock symbol: | Nasdaq: FOMX
|
| Stock price: | $9.40 at close April 14
|
| Market capitalization: | $211.58 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
